Keith Gagnon to Huntington Disease
This is a "connection" page, showing publications Keith Gagnon has written about Huntington Disease.
Connection Strength
0.612
-
Gagnon KT. HD Therapeutics - CHDI Fifth Annual Conference. IDrugs. 2010 Apr; 13(4):219-23.
Score: 0.362
-
Gagnon KT, Pendergraff HM, Deleavey GF, Swayze EE, Potier P, Randolph J, Roesch EB, Chattopadhyaya J, Damha MJ, Bennett CF, Montaillier C, Lemaitre M, Corey DR. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry. 2010 Nov 30; 49(47):10166-78.
Score: 0.094
-
Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol. 2009 May; 27(5):478-84.
Score: 0.085
-
Taki M, Rohilla KJ, Barton M, Funneman M, Benzabeh N, Naphade S, Ellerby LM, Gagnon KT, Shamsi MH. Novel probes for label-free detection of neurodegenerative GGGGCC repeats associated with amyotrophic lateral sclerosis. Anal Bioanal Chem. 2019 Oct; 411(26):6995-7003.
Score: 0.043
-
Dodd DW, Gagnon KT, Corey DR. Digital quantitation of potential therapeutic target RNAs. Nucleic Acid Ther. 2013 Jun; 23(3):188-94.
Score: 0.028